A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease

Autoimmune Disorder
Crohn's Disease
Inflammatory Bowel Disease (IBD)
Ulcerative Colitis

Results
Download
Print

Study results

LPS CA40192 FENNEL Final Results March 2024 English (PDF, 0.5 MB)

LPS_CA40192_FENNEL_final results_27Oct2021_English (PDF, 0.2 MB)

LPS_CA40192_FENNEL_final results_27Oct2021_ES (PDF, 0.7 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease

Study results

LPS CA40192 FENNEL Final Results March 2024 English (PDF, 0.5 MB)

LPS_CA40192_FENNEL_final results_27Oct2021_English (PDF, 0.2 MB)

LPS_CA40192_FENNEL_final results_27Oct2021_ES (PDF, 0.7 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease

For the latest version of this information please go to www.forpatients.roche.com